Daiichi Sankyo looks to bring FLT3 drug back from the dead with late-stage win in early AML patients
Daiichi Sankyo was on the receiving end of an FDA slapdown more than two years ago for FLT3 drug quizartinib and some flimsy data in acute myeloid leukemia. Looking to salvage a bad situation, Daiichi is now touting results in earlier AML patients with hopes for a better outcome with regulators.
Quizartinib added to a chemo regimen and then continued solo significantly extended the lives of patients with newly diagnosed acute myeloid leukemia with the FLT3-ITD mutation over chemo alone, according to topline results from the Phase III QuANTUM-FIRST study released Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.